CRUK0939 T1-R1 TRACERx lung cancer PDX

CRUK0939 T1-R1-PDX: Sample from primary NSCLC tumour collected from a White-British female, with a primary diagnosis of lung invasive adenocarcinoma (stage 3a), ex-smoker

Contributors

Inventor Institute
Robert Hynds, David Pearce CRUK Lung Cancer Centre of Excellence at University College London
Cat. #: 162270
Cancer types: Lung cancer
Cancer Subtype: NSCLC: Lung Invasive Adenocarcinoma
Gender: Female
Age, y.o.: 59
Cancer Stage or Grade: 3a
Biopsy Site: Primary lung resection
Patient ethnicity: White-British
Treatment History: Naive
Primary citation: Hynds R.E. et al., Nature Communications 15, 4653 (2024). PMID: 38821942
Alternate name: CRUK0939_PDX_T1-R1
Product description: Human non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) model generated from primary tumour from patient enrolled in the Lung TRACERx study. PDX models are highly valuable in recapitulating patient tumour characteristics. These include more representative intratumour heterogeneity, genomic features, metastatic patterns and drug responses than traditional cell line and animal models. Therefore, PDX models can be used to support accurate disease modelling and preclinical in vivo drug validation studies. This pioneering collection of TRACERx NSCLC PDX models were derived from multiple regions of primary tumours from patients enrolled in the Lung TRACERx study. This approach significantly increased PDX engraftment success and these models provide valuable insights into how well PDX models represent the intratumour heterogeneity of source patient tumours.
Initial handling information: Primary NSCLC tumour material was minced and injected subcutaneously in the flank of male NSG mice in growth factor reduced matrigel.
Additional notes: Additional information on PDX model establishment and characterisation can be found in the Product Information Sheet.
Mice Passaged: Yes
Engraftment Site: Subcutaneous (flank)
Sample Type: Minced tumour
Host Strain: NOD scid gamma (NSG) mice
Production details: Primary NSCLC tumour material was minced and injected subcutaneously in the flank of male NSG mice in growth factor reduced matrigel. To prepare frozen samples for injection, the sample cryovial was warmed in a 37°C water bath until just thawed. The whole sample was then transferred into a sterile 1.5 ml centrifuge tube and topped up with transport medium. The sample was centrifuged at 300 x g for 5 minutes and the supernatant was removed. The sample was then washed with transport medium. If required, any large pieces of tissue were collected and finely minced with a scalpel to ensure they could pass through the needle. The sample was then centrifuged again and gently resuspended in ice-cold Matrigel, and kept on ice before subcutaneous injection. When tumours reached 1.5 cm3 in volume (calculated as 0.5 x length x width2), tumours were aseptically collected and reimplanted into new mice or cryopreserved and banked.
References:

Hynds R.E. et al., Nature Communications 15, 4653 (2024). PMID: 38821942

Jamal-Hanjani M. et al.,PLoS Biol.12, e1001906 (2014). PMID: 25003555

Related Tools for PDX models

Cat. # Tool Name
162069 HCI-001 breast cancer PDX Key Info View Tool
162074 HCI-006 breast cancer PDX View Tool
162075 HCI-007 breast cancer PDX View Tool
162076 HCI-008 breast cancer PDX Key Info View Tool
162091 HCI-025 breast cancer PDX Key Info View Tool

Related News

Representative example of haematoxylin and eosin staining of CRUK0935 T1-R5 TRACERx lung cancer PDX model at early P0 passage.
PDX Models

New non-small cell lung cancer (NSCLC) patient-derived-xenograft (PDX) models now available at CancerTools.org

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.